Case 3: Molecular Testing in Recurrent Ovarian Cancer

Case 3: PARP Inhibition in Recurrent Ovarian CancerПодробнее

Case 3: Recurrent Ovarian Cancer, Platinum-Sensitive, BRCA WTПодробнее

Case 3: Second-Line Therapy for Recurrent Ovarian CancerПодробнее

Molecular Testing for BRCA1 in Ovarian CancerПодробнее

Ovarian Cancer: Molecular Testing and PARP InhibitorsПодробнее

Introduction: Molecular Testing in Ovarian CancerПодробнее

Case 3: Maintenance Therapy for Recurrent Ovarian CancerПодробнее

Molecular Testing in Ovarian CancerПодробнее

Case 3: Benefit of PARP Inhibitor Maintenance in Ovarian CancerПодробнее

Biomarkers and Molecular Testing in Ovarian CancerПодробнее

Ovarian Cancer: Considerations for Molecular TestingПодробнее

Germline Testing in Stage IIIc Ovarian CancerПодробнее

Using Trapelo to Maintain Molecular Testing Guidelines for Ovarian CancerПодробнее

Dr. Dottino on Molecular Detection of Recurrent Ovarian CancerПодробнее

Case-Based Overview: Pretreated Recurrent Ovarian CancerПодробнее

Case 3: The OCEANS and GOG-0213 Trials for Ovarian CancerПодробнее

Gene Testing and Treatment for Recurrent Ovarian CancerПодробнее

Case 3: NGS Testing in Patients With CRCПодробнее

Effective Molecular Testing in Ovarian & Uterine Cancers To Improve OutcomesПодробнее